Teva Pharma (TEVA) Tops Q1 EPS by 11c

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $1.36, $0.11 better than the analyst estimate of $1.25. Revenue for the quarter came in at $5 billion versus the consensus estimate of $4.84 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in